In response to investor interest, Hadasit Bio-Holdings Ltd. issued American Depositary receipts (ADR's), in partnership with The Bank of New York to expose US investors to the company. After a June launch, market makers joined on making it possible to trade stock in the United States on the OTC Bulletin Board Exchange under the symbol "HADSY". This allowed foreign investors who are familiar with the Hadassah Hospital, its exceptional level of medical care and innovation, as well as the wider, general investment community who views Israel as an innovative force in the Biomed and Life Sciences field, to easily access Hadasit Bio-Holdings Ltd. stock in the USA.
Our unique holding company model extending a private hospital in to the public market has attracted global interest. Delegations from all over the world including China, Sweden, Russia and the USA have studied our business to explore the model and potential partnership possibilities.
Investment options in new and fascinating companies are constantly being examined as our current portfolio matures. In order to manage risk and to utilize the relative advantage Hadasit Bio has as a holding company with a hospital in its back yard, we have developed an innovative business model for these investments. The model is based on a relatively small initial investment for the purpose of financing a feasibility trial with one of Hadassah's specialists, while receiving the option of investing significantly more and under better conditions after the success of the trial.
Following is a concise study of the prominent portfolio companies of Hadasit:
Thrombotech is involved in the development of
|SOURCE Hadasit Bio-Holdings Ltd.|
Copyright©2010 PR Newswire.
All rights reserved